查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1133479

全球注射用水市場 - 2022-2029

Global Water for Injection Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

注射用水市場的增長是由對特定治療用途的蛋白質和疫苗等藥物需求的增加、醫療設施的快速發展、對仿製藥的需求以及癌症和心血管疾病等各種疾病帶來的。大約由於越來越流行

增加對藥物開發的投資有望推動市場增長

癌症和心血管疾病等各種疾病的患病率上升預計將在預測期內提振市場。水是我們身體組織的重要組成部分，約占我們總重量的70%。正常成人每日需要 2 至 3 升，用於通過汗液和尿液排出的不可接觸的液體。無菌注射用水，當作為藥物載體腸胃外給藥時，在引入足夠的溶質以達到每升 112 mol 的滲透壓增加後，提供了腸胃外液體補充的來源。此外，最近的市場機會導致服務提供商對先進製造設施進行重大投資。例如，2021年1月，賽默飛世爾科技宣布以8.75億美元收購諾華賽在比利時的病毒載體製造業務Henogen S.A.，並宣布提供病毒載體製造服務。 Fujifilm Corporation 還向 Fujifilm Diosynth Biotechnologies 投資了約 9.28 億美元，這是一家生物製劑和先進治療藥物 CDMO。

對藥物開發的投資增加導致研究活動增加，這對注射用水市場產生了積極影響。

注射用水成本高阻礙市場增長

但是，與註射用水相關的副作用包括靜脈發炎（可能由於注射技術而發生）和注射部位疼痛。此外，長期患有肝腎疾病的患者在開始注射用水前應諮詢醫生。此外，哺乳母親不能直接飲用注射用水，這可能會對市場增長產生負面影響。

COVID-19 影響分析

COVID-19 的出現對全球注射水市場產生了重大影響。近年來，主要通過腸胃外給藥的複雜癌症療法和新冠病毒疫苗等生物製劑的不斷增長，增加了對先進製造支持的需求，使得合同開發和製造組織 (CDMO) 發揮了重要作用。生物製劑的這種進步為市場上的主要參與者提供了機會。例如，Greenlight Biosciences 和全球 CDMO Samsung Biologics 已合作為三星生物生產大量 Greenlight 的信使 RNA 候選疫苗 COVID-19。該合作夥伴關係旨在推動 Greenlight 的 COVID-19候選疫苗進入 III 期臨床試驗和批准後的商業銷售生產。另一方面，我們面臨全球供應鏈中斷、生產設施停工、耗材和材料供應短缺、產能短缺等問題。臨床試驗經常被取消或推遲。然而，只要 COVID-19 疫情好轉，所有開放和受監管的原材料供應鏈設施都會為製藥和生物製藥公司創造機會，從而推動市場增長。

全球注射用水市場報告將提供對大約 50 多個市場數據表、50 多個圖表和 200 頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按應用：市場細分
  • 按最終用戶：市場細分
  • 按分銷渠道：市場細分
  • 按地區：市場細分

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 心血管疾病發病率上升
      • 研究活動增加
    • 限制因素
    • 嚴格監管
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按應用程序

  • 臨床藥理學
  • 藥物稀釋
  • 抗菌用途
  • 其他

第 8 章最終用戶

  • 製藥公司、生物技術公司
  • 研究所
  • 醫院
  • 診所
  • 其他

第 9 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 12 章公司簡介

  • 雅培實驗室
    • 公司概況
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • AdvaCare Pharma
  • B. Braun SE
  • FUJIFILM Holdings Corp.
  • GlaxoSmithKline Plc
  • Merit Healthcare International Inc.,
  • Novartis AG
  • Pfizer Inc.
  • Pharma Cure Laboratories
  • Sanofi

第 13 章全球可注射水市場-DataM

簡介目錄
Product Code: DMPH5852

Market Overview

Water for Injection Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Water for Injection (WFI) is a water quality standard described by pharmacopeial groups globally. It is used for many essential pharmaceutical products and applications, including necessary use for hemofiltration, irrigation, injectable drugs, in the production of some active pharmaceutical ingredients, implantable medical devices, and other various applications.

Market Dynamics

The Water for Injection market growth is driven by the rising demand for medicines such as proteins and vaccines for specific therapy, rapid advancement in healthcare facilities, demand for generic formulations, and increasing prevalence of different disease such cancer and cardiovascular disease.

The rising investment in the development of drugs is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. Water is a critical component of our body tissues and accounts for around 70% of total body weight. Average normal adult daily requirements range from two to three liters each for insensible water loss by perspiration and urine production. When it is administered parenterally as a vehicle for drugs, sterile water for injection offers a source of water for parenteral fluid replenishment after sufficient solute is introduced to reach an osmolarity of 112 mol per liter. In addition, recent market opportunities have service providers making remarkable investments in advanced manufacturing facilities. For instance, in January 2021, Thermo Fisher Scientific announced its viral vector manufacturing services through the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for $875 million. Also, Fujifilm Corp. invested around $928 million in Fujifilm Diosynth Biotechnologies, a CDMO of biologics and advanced therapies.

Increasing investment in drug development leads to increasing research activities, which positively impacts on water for injection market.

The high cost of water for injection will hamper the growth of the market

However, the side effects related to water for injections such as inflammation of a vein (that may occur due to the technique of injecting) and pain at the injected site. Also, liver and kidney patients with a long history of this disease have to consult their doctor before starting the water for injection. In addition, a nursing mother cannot take water for injection directly this have a negative impact on the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global water for injection market. Recently increasing pipeline of biologics, including complex oncology products moslty delivered parenterally, and COVID vaccine production, there is rising demand for technically advanced manufacturing support, in which contract development and manufacturing organizations (CDMOs) are playing a vital role. These advancemnt in biologics provides the opportunity to the key players in the market. For instance, GreenLight Biosciencesand Samsung Biologics, a global CDMO, collaborated, in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at large scale. This collaboration aims to drive the production of GreenLight's COVID-19 vaccine candidate for Phase III trials and, it is subject to regulatory approval, commercial sales. On the other hand, global supply chains disruptions, iterupptions in manufacturing facilities, the more companies faced lack of supply of consumables, commodities, and fill-finish capacity. There are many clinical trials were cancelled or postponed. But as far as the situation of COVID-19 is recovering all facilities are opened and regulated supply chains of raw material gives opportunity to pharma and biophrma companies which is drirng the market growth.

Segment Analysis

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pharmaceutical & biotechnology companies segment is expected to boost the market over the period of the forecast. The WFI is essential for drug formulations and other activities in pharma and biotech companies. As per the European medicines agency, 2020 data report, The European Pharmacopoeia provided quality standards for types of water for pharmaceutical use including Purified Water Water for Injections (WFI), and Water for preparation of extracts. The WFI is used in many sterile medicinal products such as biologics, parenteral, haemodiafiltration solutions, peritoneal dialysis solutions, and irrigation solutions. Also, in 2020, Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP), agreed that the monograph mentioned in The International Pharmacopoeia (Water for injections) and the guideline World Health Organization Good manufacturing practices: water for pharmaceutical use is WFI. Moreover, in pharma companies there are so many activities are performed including drug formulation. For instance, in the manufacturing process of injectable products, such as diluting or dissolving drug substances or preparations during the manufacturing of parenteral products, and for the manufacture of water for the preparation of injections. Bulk WFI can be utilized for the end of the cleaning of equipment which is come into contact with injectable products and final rinse to make sure that no subsequent thermal or chemical deproteinization process is applied.

Geographical Analysis

North America region holds the largest market share of the global water for injection market

North America dominates the market for water for injection and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of a large number of key players, an advanced healthcare system, and rising research and development activities. To develop a drug, there is a need to follow regulatory guidelines such as the United States Pharmacopoeia (USP). In addition, due to technology advancements, the key players are designed to meet the needs of the pharmaceutical industry and provide an inexpensive method for producing WFI. For instance, Evoqua's VRx system offers ease of use, carbon filtration, reverse osmosis, UV light, particle filtration, electrodeionization, and ultra-filtration technologies. The VRx system offers users reliable, high-quality WFI.

Furthermore, the new term coming into the market is "Cold WFI''. It has an ambient temperature of both cold and hot WFI are softened and dechlorinated with RO, but the main difference between both types of WFI systems is that cold WFI systems use a second membrane barrier, such as low-pressure ultrafiltration, to ensure microbiological quality in place of energy-intensive distillation processes.

Competitive Landscape

The water for injection market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International Inc., Novartis AG, Pfizer Inc., Pharma Cure Laboratories and Sanofi among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the water for injection market globally.

For instance,

  • In July 2021, Nexus Pharmaceuticals launched potassium chloride in water for injection in single-dose IV bags of 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL. This will be available in environmentally friendly cartons of 24 IV bags.
  • In 2022, WuXi STA, has announced its first parenteral formulation manufacturing line at the Wuxi city site. In this manufacturing plant fully automatic sterile manufacturing line operates in a full isolation system with an annual capacity of 2 million units.

B. Braun Medical Inc.

Overview:

B. Braun is a German medical and pharmaceutical device company, founded in 1839 and presence in more than 60 countries. It provides healthcare products and it has an out-patient division.

Treatment type Portfolio:

Sterile Water for Injection: It is a colorless, clear, odorless liquid. It is hypotonic, sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. It is a diluent or solvent suitable for intravascular injection after first having been made nearly isotonic by the addition of a suitable solute. It is available in different volumes such as 1L, 2L, and 3L, 250mL, and 500 ML.

The global water for injection market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Application
  • 3.2. Market Snippet By End User
  • 3.3. Market snippet By Distribution channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of cardiovascular diseases
      • 4.1.1.2. The increasing number of research activities
    • 4.1.2. Restraints:
    • 4.1.3. The stringent regulations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Clinical Pharmacology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Medication Dilution
  • 7.4. Anti-bacterial Application
  • 7.5. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Pharmaceutical & Biotechnology Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Research Institutes
  • 8.4. Hospitals
  • 8.5. Clinics
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AdvaCare Pharma
  • 12.3. B. Braun SE
  • 12.4. FUJIFILM Holdings Corp.
  • 12.5. GlaxoSmithKline Plc
  • 12.6. Merit Healthcare International Inc.,
  • 12.7. Novartis AG
  • 12.8. Pfizer Inc.
  • 12.9. Pharma Cure Laboratories
  • 12.10. Sanofi

LIST NOT EXHAUSTIVE

13. Global Water for Injection market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us